Benoît Schreck1, Nicolas Wagneur2, Pascal Caillet3, Marie Gérardin4, Jennyfer Cholet5, Michel Spadari6, Nicolas Authier7, Juliana Tournebize8, Marion Gaillard9, Anais Serre10, Louise Carton11, Stéphanie Pain12, Pascale Jolliet13, Caroline Victorri-Vigneau14. 1. Addictovigilance des Pays de la Loire, Service de pharmacologie clinique, Institut de biologie, CHU de Nantes, 44093 Nantes Cedex 1, France. Electronic address: benoit.schreck@chu-nantes.fr. 2. Addictovigilance des Pays de la Loire, Service de pharmacologie clinique, Institut de biologie, CHU de Nantes, 44093 Nantes Cedex 1, France. Electronic address: nicolas.wagneur@gmail.com. 3. Addictovigilance des Pays de la Loire, Service de pharmacologie clinique, Institut de biologie, CHU de Nantes, 44093 Nantes Cedex 1, France. Electronic address: pascal.caillet@chu-nantes.fr. 4. Addictovigilance des Pays de la Loire, Service de pharmacologie clinique, Institut de biologie, CHU de Nantes, 44093 Nantes Cedex 1, France. Electronic address: marie.gerardin@chu-nantes.fr. 5. Service universitaire de psychiatrie et d'addictologie de liaison, CHU de Nantes, 44093 Nantes Cedex 1, France. Electronic address: jennyfer.cholet@chu-nantes.fr. 6. Addictovigilance Marseille, Laboratoire de pharmacologie médicale et clinique, Groupe Hospitalier La Timone, 13385 Marseille Cedex 5, France. Electronic address: michel.spadari@ap-hm.fr. 7. Addictovigilance Auvergne, Hôpital G. Montpied, Service de Pharmacologie Médicale, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand Cedex, France. Electronic address: nauthier@chu-clermontferrand.fr. 8. Addictovigilance Nancy, Hôpital Central, Pavillon Bruillatre Balbatre, CHU de Nancy, 54035 Nancy Cedex, France. Electronic address: j.tournebize@chru-nancy.fr. 9. Addictovigilance Bordeaux, Service de pharmacologie médicale, Hôpital Pellegrin, CHU de Bordeaux, 33076 Bordeaux Cedex, France. Electronic address: marion.gaillard85@gmail.com. 10. Addictovigilance Montpellier, Service de pharmacologie médicale et toxicologie, Hôpital Lapeyronie, CHU de Montpellier, 34294 Montpellier Cedex 5, France. Electronic address: anais-serre@chu-montpellier.fr. 11. Addictovigilance du Nord-Pas-de-Calais, Service de pharmacologie médicale, CHRU de Lille, 59045 Lille Cedex, France. Electronic address: louise.carton@chru-lille.fr. 12. Addictovigilance Poitiers, Service de pharmacologie clinique et vigilances, CHU de Poitiers, 86021 Poitiers Cedex, France. Electronic address: stephanie.pain@univ-poitiers.fr. 13. Addictovigilance des Pays de la Loire, Service de pharmacologie clinique, Institut de biologie, CHU de Nantes, 44093 Nantes Cedex 1, France; INSERM UMR U1246 SPHERE, Institut de Recherche en Santé 2, 22 Boulevard Benoni-Goullin, 44200 Nantes, France. Electronic address: pascale.jolliet@univ-nantes.fr. 14. Addictovigilance des Pays de la Loire, Service de pharmacologie clinique, Institut de biologie, CHU de Nantes, 44093 Nantes Cedex 1, France; INSERM UMR U1246 SPHERE, Institut de Recherche en Santé 2, 22 Boulevard Benoni-Goullin, 44200 Nantes, France. Electronic address: caroline.vigneau@chu-nantes.fr.
Abstract
BACKGROUND: Cannabinoid hyperemesis syndrome is a variant of cyclical vomiting syndrome in a context of chronic cannabis usage. Our aim was to compare French cases to those identified in the international literature in order to further our knowledge of the clinical criteria, pathophysiology and treatments for cannabinoid hyperemesis syndrome. METHODS: We analysed cases reported in the international literature up to 30 June 2017, obtained from the MEDLINE, PsycINFO and The Cochrane Library databases; we selected relevant articles based on title and abstract. We also analysed cases of cannabinoid hyperemesis syndrome reported to the French addictovigilance network. RESULTS: A systematic search through the three databases enabled us to identify 137 articles. Finally, 55 articles were selected as they involved reported cases. In total, 113 cases were reported in these 55 articles. We were thus able to analyse 29 reported French cases of cannabinoid hyperemesis syndrome. Cannabinoid hyperemesis syndrome mainly affects young male subjects who have been smoking cannabis daily for several years. Taking hot baths or showers is the most effective means of relieving the symptoms, while antiemetics and dopamine antagonists do not appear to effective for relieving nausea and vomiting. CONCLUSIONS: French cases display the same characteristics as the cases identified in the international literature. The pathophysiology of cannabinoid hyperemesis syndrome is unclear and several hypotheses have been put forward in the literature. We have only begun to characterise the syndrome, though there is an outbreak of cannabinoid hyperemesis syndrome in France.
BACKGROUND:Cannabinoid hyperemesis syndrome is a variant of cyclical vomiting syndrome in a context of chronic cannabis usage. Our aim was to compare French cases to those identified in the international literature in order to further our knowledge of the clinical criteria, pathophysiology and treatments for cannabinoid hyperemesis syndrome. METHODS: We analysed cases reported in the international literature up to 30 June 2017, obtained from the MEDLINE, PsycINFO and The Cochrane Library databases; we selected relevant articles based on title and abstract. We also analysed cases of cannabinoid hyperemesis syndrome reported to the French addictovigilance network. RESULTS: A systematic search through the three databases enabled us to identify 137 articles. Finally, 55 articles were selected as they involved reported cases. In total, 113 cases were reported in these 55 articles. We were thus able to analyse 29 reported French cases of cannabinoid hyperemesis syndrome. Cannabinoid hyperemesis syndrome mainly affects young male subjects who have been smoking cannabis daily for several years. Taking hot baths or showers is the most effective means of relieving the symptoms, while antiemetics and dopamine antagonists do not appear to effective for relieving nausea and vomiting. CONCLUSIONS: French cases display the same characteristics as the cases identified in the international literature. The pathophysiology of cannabinoid hyperemesis syndrome is unclear and several hypotheses have been put forward in the literature. We have only begun to characterise the syndrome, though there is an outbreak of cannabinoid hyperemesis syndrome in France.
Authors: Thangam Venkatesan; David J Levinthal; B U K Li; Sally E Tarbell; Kathleen A Adams; Robert M Issenman; Irene Sarosiek; Safwan S Jaradeh; Ravi N Sharaf; Shahnaz Sultan; Christopher D Stave; Andrew A Monte; William L Hasler Journal: Neurogastroenterol Motil Date: 2019-06 Impact factor: 3.598
Authors: Deepika Slawek; Senthil Raj Meenrajan; Marika Rose Alois; Paige Comstock Barker; Irene Mison Estores; Robert Cook Journal: J Prim Care Community Health Date: 2019 Jan-Dec